{"subsection_name": null, "pub_date": "2011-10-28T15:28:15Z", "byline": {"original": "By ANDREW POLLACK", "person": [{"lastname": "POLLACK", "organization": "", "rank": 1, "role": "reported", "firstname": "Andrew"}]}, "abstract": "The new treatments were approved only last spring.", "word_count": 621, "print_page": null, "news_desk": null, "snippet": "The new treatments were approved only last spring.", "multimedia": [], "source": "The New York Times", "blog": [], "keywords": [{"name": "organizations", "value": "Merck & Company Inc", "rank": "4"}, {"name": "subject", "value": "Hepatitis", "rank": "3"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "2"}, {"name": "organizations", "value": "Vertex Pharmaceuticals Inc", "rank": "5"}, {"name": "type_of_material", "value": "News", "rank": "1"}, {"name": "unknown", "value": "Merck & Company Inc|MRK|NYSE", "rank": "6"}, {"name": "unknown", "value": "Vertex Pharmaceuticals Inc|VRTX|NASDAQ", "rank": "7"}], "type_of_material": "Blog", "lead_paragraph": "Updated: 4:45 p.m. In the closely watched bout between two new hepatitis C drugs, it's a knockout in the first round.", "web_url": "http://prescriptions.blogs.nytimes.com/2011/10/28/vertex-bests-merck-in-new-hepatitis-c-drug-sales/", "section_name": "Health", "headline": {"main": "Vertex Bests Merck in New Hepatitis C Drug Sales", "kicker": "Prescriptions"}, "slideshow_credits": null, "_id": "4fd3a1338eb7c8105d8e7967", "document_type": "blogpost"}